BACKGROUND: Alterations of DNA methylation have been reported in many human cancers. In prostatic carcinoma, hypermethylation of the GST P gene promoter and an overall decrease in methylcytosine content have been reported. The aim of the present study was to investigate the frequency and extent of these alterations in relation to tumor stage and grade, in order to explore their clinical relevance and to determine their relationship to each other. METHODS: DNA from 32 histologically verified adenocarcinomas of the prostate was analyzed for GST P hypermethylation by a semiquantitative PCR method and for overall DNA methylation by quantitative Southern blot analysis or LM-PCR of LINE-1 repetitive sequence methylation. RESULTS: GST P hypermethylation was detected in 24/32 (75%) specimens, and LINE-1 hypomethylation in 17/32 (53%). Both alterations tended to increase in frequency and extent with tumor stage. All but 1 of 8 carcinomas with lymph node involvement were positive for GST P hypermethylation. Six of these as compared to 2 out of 24 showed strong hypomethylation (P = 0.005). Hypermethylation and hypomethylation did not show a quantitative correlation, but all except two samples with weak LINE-1 hypomethylation also displayed GST P hypermethylation. CONCLUSIONS: GST P hypermethylation is an extremely frequent change in prostatic carcinoma which most probably precedes genome-wide hypomethylation. It appears useful for sensitive detection of prostatic carcinoma, whereas pronounced LINE-1 hypomethylation may be associated with progressive tumors.
BACKGROUND: Alterations of DNA methylation have been reported in many humancancers. In prostatic carcinoma, hypermethylation of the GST P gene promoter and an overall decrease in methylcytosine content have been reported. The aim of the present study was to investigate the frequency and extent of these alterations in relation to tumor stage and grade, in order to explore their clinical relevance and to determine their relationship to each other. METHODS: DNA from 32 histologically verified adenocarcinomas of the prostate was analyzed for GST P hypermethylation by a semiquantitative PCR method and for overall DNA methylation by quantitative Southern blot analysis or LM-PCR of LINE-1 repetitive sequence methylation. RESULTS:GST P hypermethylation was detected in 24/32 (75%) specimens, and LINE-1 hypomethylation in 17/32 (53%). Both alterations tended to increase in frequency and extent with tumor stage. All but 1 of 8 carcinomas with lymph node involvement were positive for GST P hypermethylation. Six of these as compared to 2 out of 24 showed strong hypomethylation (P = 0.005). Hypermethylation and hypomethylation did not show a quantitative correlation, but all except two samples with weak LINE-1 hypomethylation also displayed GST P hypermethylation. CONCLUSIONS:GST P hypermethylation is an extremely frequent change in prostatic carcinoma which most probably precedes genome-wide hypomethylation. It appears useful for sensitive detection of prostatic carcinoma, whereas pronounced LINE-1 hypomethylation may be associated with progressive tumors.
Authors: C Daniel Eller; Moira Regelson; Barry Merriman; Stan Nelson; Steve Horvath; York Marahrens Journal: Gene Date: 2006-10-05 Impact factor: 3.688
Authors: R Zelic; V Fiano; C Grasso; D Zugna; A Pettersson; A Gillio-Tos; F Merletti; L Richiardi Journal: Prostate Cancer Prostatic Dis Date: 2014-11-11 Impact factor: 5.554
Authors: M Ehrlich; C B Woods; M C Yu; L Dubeau; F Yang; M Campan; D J Weisenberger; Ti Long; B Youn; E S Fiala; P W Laird Journal: Oncogene Date: 2006-04-27 Impact factor: 9.867
Authors: Masashi Nakayama; Christina J Bennett; Jessica L Hicks; Jonathan I Epstein; Elizabeth A Platz; William G Nelson; Angelo M De Marzo Journal: Am J Pathol Date: 2003-09 Impact factor: 4.307